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Cellular Mechanisms of Somatostatjn Action in the Gut 
John DelValle, Jung Park, Tsutomu Chiba, and Tadataka Yamada 
We have used isolated canine parietal cells to examine the receptor and postreceptor events mediating the inhibii effects of 
sumatostatin on acid secretion. Somatostatin-14 (514) and somatostatin-28 (528) dose dependently inhibited parietal cells stim- 
ulated by secretagogues that activate both the adenylate cyclase/cyclic adenosine monophosphate and the inositol phospholipid/ 
protein kinase C cascades. The inhibitory action was mediated via a specific cell surface receptor that consists of a single subunit 
protein (molecular weight §g,ooO d). This receptor recognized S14 and S28 equally well. Sornatostatin inhiied parfetal cell 
activity via mechanisms that are both dependent on and independent of a pertussis toxin-sensitive inhibitory guanine nucleotide 
binding protein. 
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S INCE ITS initial isolation from sheep hypothalamus,’ somatostatin has been found in many areas throughout 
the body including the gastric mucosa.2 Both in vivo and in 
vitro studies have demonstrated that somatostatin is released 
into the circulation in response to nutrient ingestion,’ reach- 
ing plasma concent~tions that are sufficient to inhibit gastric 
acid secretion.4 In addition, somatostatin containing D-cells, 
which are found throughout the fundic mucosa, contain long 
cytoplasmic processes’ extending to parietal cells, suggesting 
a local or paracrine regulatory role for this peptide on acid 
secretory cell function. Despite the abundance ofin vitro and 
in vivo studies examining the effect of somatostatin on acid 
secretion, its direct action on parietal cell function continues 
to be a source of debate. The present studies demonstrate 
our efforts to elucidate the receptor and postreceptor events 
important in mediating somatostatin’s regulatory action on 
parietal cells. 
MATERIALS AND METHODS 
Reagents 
Somatostatin-14 (S14), somatostatin-28 (S28), [Leu*-D-Trpz2- 
Ty?]S28 (S28-A), and pentagastrin were purchased from Peninsula 
Laboratories (Belmont, CA). NaizsI, [‘4C] aminopy~ne (80 &i/ 
nmol), myo-[2-‘H] inositol (15.8 Ci/mmol), and [32P] orthophos- 
phoric acid (carrier free) were obtained from DuPont-New EnaJand 
Nuclear (Boston, MA). Cyclic adenosine monophosphate (CAMP) 
assay kits, [m-32P] adenosine triphosphate (ATP) ( 10 to 15 Cifmmol), 
tissue solubihzer (NCS), and aqueous scintillation cocktail (ACS) were 
from Amersham (Arlington Heights, IL). Earle’s balanced salt solution 
(EBSS) and Ham’s F-l2/DulbecaYs modified Eagle’s (S&SO) medium 
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(HF-IZ/DMEM) were obtained from Irvine Scientific (Santa Ana, 
CA). All other chemicals were from Sigma (St Louis, MO). 
Cell Preparation 
Canine parietal cells were isolated and enriched using a modification 
of the technique pmviously described by SOB6 Freshly obtained canine 
fundic mucosa was thinly sliced and exposed serialiy to incubations 
with collagenase (0.35 mg/mL) and EDTA (1 mmol/L). Parietal cells 
were enriched to greater than 95% homogeneity using counterflow 
elutriation followed by density gradient ~nt~u~tion (50% percoll) 
of the acutely dispersed cells.’ The uptake of [14C] aminopyrine was 
used as a measure of parietal cell acid secretory activity.* Enriched 
parietal cells (2 X lo6 cells/ml) were incubated with 0. I pCi of [‘Cl 
aminop~ne and the reagents to be tested for 20 minutes. Cetts were 
then pelleted, solubilized in NCS, and counts were determined in a 
liquid scintillation counter after adding ACS. 
Receptor minding Studies 
The somatostatin ligand S28-A was labeled with Na’2SI using 
chloramine-T and purified by gel hltration.9 The specific activity of 
the ligand obtained was 2,ooO Cifmmol. Binding studies with parietal 
cells were performed as previously described.q For receptor cross- 
linking, ?-S28-A was incubated either with intact cells for 1 hour 
at 37’C or with membranes for 2 hours at 25°C and then in 500 
pmol/L disu~inimidyi suberate for 15 minutes at 0°C. After solu- 
bilixation in 62.5 mmol/L Tris buffer(pH 6.8)containing 2% sodium 
dodecyl sulfate (SDS), the preparations were applied to SDS poly- 
acrylamide gel electrophoresis and the gels were examined by auto- 
radiography. 
Signal Transduction Studies 
After incubating parietal cells (2 X IO6 cells/ml) with various re- 
agents for 15 minutes in EBSS at 37°C the reaction was terminated 
by adding ice chilled trichloroacetic acid for 15 minutes. Following 
centrifugation of the reaction mixture and ether extraction of the 
supematant, CAMP was quantified by a protein binding assay’* using 
a commercially available kit. Mobili~tion of membrane inosito. 
phospholipids in parietal cell membranes was determined using pre- 
viously described methods. “-‘4 Membrane-associated protein kinase 
C activity was measured in parietal cells treated with various secre- 
tagogues using methods previously described by Kikkawa et al.” For 
measurement ofcytosolic calcium [Ca’+]i, purified parietal cells were 
loaded with Fura- AM (1 pmol/L) then attached to a cell-tak coated 
coverslip placed in a tlow through chamber; fluorescence (340 and 
380 nm) was measured in a single parietal cell using a Nikon Diaphot 
inverted microscope (Garden City, NY) coupled to a Spex (DM 3,000- 
cm) spectrofluorometric system (Edison, NJ). Parietal cell auto flu- 
orescence was subtracted from each experiment and [Ca”]i calibra- 
tion was perfonned using ~tonin (75 FmolfL) and EGTA (4 mmol/ 
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L). [Ca*+]i was calculated using the equation developed by Gryn- 
kiewicz et al.I6 
RESULTS AND DISCUSSION 
As shown in Fig 1, both S 14 and S28 inhibited pentagastrin 
plus isobutyl me~ylxan~ne (IMX~stimula~ parietal cell 
activity in a dose-dependent fashion. Similar inhibitory results 
were obtained when parietal cells were stimulated with either 
carbachol, histamine, forskolin, or dibutyryl CAMP. Corre- 
lation of ~rnat~~tin’s biological activity with binding to a 
specific cell surface receptor required radio&and studies using 
‘25I S-28A. ‘25I S-28A bound to isolated enriched parietal 
cells in a specific and time-dependent fashion. Binding in- 
hibition studies performed with both S28 and S14 showed 
almost superimposable displacement of bound radioligand 
in a dose-dependent manner, with half maximal inhibition 
occurring at con~ntrations of 4.2 * 1.3 X 10T9 mol/L (n 
= 6) and 9.4 f 2.2 X 10m9 mol/L (n = 6) for Sl4 and S28, 
respectively (Fig 2). Evaluation of the somatostatin binding 
data through Scatchard analysis showed the presence of both 
high-affinity (I& = 3.2 X 10m9 mol/L) and low-affinity (K,, 
= 2.1 X lo-’ mol/L) binding sites on parietal cells. Of note 
is the close correlation between the & of the high-affinity 
receptor (9.2 * 2.2 X foe9 mol/L) and the ~oncen~ations of 
S28 and S14 required for half maximal inhibition of acid 
secretion (Fig 1). These data confirm the presence of a func- 
tional somatostatin receptor on parietal cells. Our studies 
indicate that this receptor recognizes S14 and S28 equally 
well, unlike somatostatin receptors in other cell systems.“~” 
In an attempt to characterize the somatostatin receptor 
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Fii 1. S14- and SZE-mediated inhibition of pentegastrin (1 O-’ 
mol/L) and IMX (lo+ mol/L)-stimulated aminopyrine uptake in iso- 
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Fig 2. Inhibition of ‘?-[Leu%-Tfl-Ty?JS28 binding to gastric 
~lcsltsbyS14andS28.Resu~am~Mapercentsge 
of binding in the absence of unlabeled peptidee (B/Be). 
suberate to both intact cells and membranes obtained from 
purified parietal cells. A single band of specific crosslinking 
with a molecular weight of 102 kd was obtained. Both S14 
and S28 competitively inhibited crosslinking in a dose-de- 
pendent fashion with 50% inhibition occurring at 10W7 to 
IO-* molfL for both peptides. The pattern and kinetics of 
crosslinking was not altered by increased parietal cell purity 
but the amount of nonspecific labeling was reduced substan- 
100 
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Fig 3. Eifect of eometoetetin on pwiatal ceil [“C] aminopyrine 
uptake and CAMP production induced by histamine (lOA mol/L) 
plus IMX (lo4 mol/L). 
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Table 1. Effects of Acid Secretagogues on [‘%I Aminopyrine Uptake and CAMP Production in, Release of [3H] lnositol Trisphosphate 
(SH-IPs) from, and 52P-Labeling of Phosphatidic Acid, Phosphatidyl Inositol, and Phosphatidyl lnositol Bisphosphate in Parietal Cells 
AP-uptake CAMP 3H-tP, PA PI PIP* 
Stimulant @I = 4) (I7 = 5) (n = 6) In = 6) (n = 6) (n = 6) 
Histamine (1 O-’ mol/L) 508 ? 46t 163+ Ilt 108*5 106i4 110+ 12 97 * 4 
Forskolin (1 Oe4 mol/L) 1,414* 114 517 t47t 101 + 8 105_t3 109 i 10 99 ?I 5 
dbcAMP f 1 Om3 mot/L) 1.300*216t NT 103” 6 98 I!Z 4 106 i 7 10024 
Carbachol(1 O-4 mol/L) 1,499 ?z 187t 103 rt 15 265 +I 18t 173 rt 17t 333 i 12t 73 -+ 51 
Pentagastrin (1 O-’ mol/L) 421 ? 64t 96rt 14 192 * 14t 143 + 26t 205 + 14t 79 + 5’ 
NOTE. Data are expressed as means + SE percent of unstimutated control values. 
Abbreviations: AP, aminopyrine; 3H-IP3, j3H] (tritiated) inositol t&phosphate; NT, not tested; PA, phosphatidic acid; Pi, phosphatidyl inositoi; PIP1, 
phosphatidyl inositol bisphosphate. 
* P < .05 v control. 
t P < .Ol v control. 
tially. In addition, the size of the crosslinked band was not 
altered by treatment of preparations with dithiotreitol in 
concentrations as large as 100 mmol/L. These data suggest 
that the parietal cell somatostatin receptor is a single subunit 
protein with a molecular weight of 99,000 (after subtracting 
the molecular weight of S-28A). 
We next examined the intmcellular m~hanisms respon- 
sible for somatostatin’s inhibitory effects on acid secretion. 
Somatostatin dose dependently inhibited aminopyrine uptake 
and CAMP accumulation in parietal cells in a parallel fashion 
(Fig 3). Pretreatment of parietal cells with pertussis toxin 
(100 ng/mL) reversed the inhibitory effect of somatostatin 
on forskolin- and histamine-mediated acid secretion but did 
not alter somatostatin’s inhibitory action on dibutyryl CAMP 
and ~n~~st~n-m~iated aminopy~ne accumulation. Ad- 
ditional experiments showed that somatostatin’s inhibitory 
action on CAMP accumulation induced by histamine and 
forskolin was also reversed by pertussis toxin pretreatment. 
These data are consistent with the notion that, in addition 
to inhibiting adenylate cyclase via a pertussis toxin-sensitive 
guanine nucleotide binding protein, somatostatin may exert 
its action on target cells at a point distal to the production 
of CAMP. 
Previous studies have demonstrated that both gas&in and 
carbachol stimulate parietal cells through a membrane ino- 
Table 2. Effects of Acid Secretagogues on Membrane- 
Associated Protein Kinase C Activity in Parietal Cells 
Protein Kinase C Activity 
Condiiion (pmol S2P/min~ mg Protein) 
Control 70.6 i 6.3 
Histamine (1 O-” mol/L) 71.5+6.5 
dbcAMP (1 0e3 mol/L) 68.4 z? 5.8 
Carbachol ( lOa mol/L) 122.5 f 6.5’ 
PG (1 O-’ mol/L) 112.9 + 6.2’ 
TPA (1 O-’ mol/L) 132.2 5 11 .O” 
NOTE. Data are expressed as means f SEM (n = 6). 
Abbreviations: PG, pentagastrin; TPA, tetradecanoyl-phorbol-13-ac- 
etate. 
l P c .Ol v control. 
sit01 phospholipid/protein kinase C-dependent pathway. As 
shown in Tables I and 2, although somatostatin inhibited 
both ~n~gast~n and c~bachol-mediated stimulation of 
aminopyrine uptake in a dose-dependent manner, it had no 
effect either on the turnover of membrane inositol phospho- 
lipids or on the activation of protein kinase C induced by 
these two agents. These results suggest that somatostatin’s 
inhibitory effect on parietal cells occurs at a distal point in 
the signal transduction cascade activated by gastrin and car- 
bachol. 
Previous investigators have demonstrated an effect of so- 
matostatin on regulating [Ca”]i in various cell typesi9,” Ac- 
cordingly, we examined the effect of somatostatin on car- 
bachol and gastrin-mediated increases in [Ca*‘]i in parietal 
cells and observed that maximum concentrations of somato- 
statin ( 10e6 mol/L) failed to alter resting [Ca*‘]i or the initial 
transient increase in [Ca’“]i stimulated by maximal effective 
doses of carbachol or gas&in. Preliminary studies also suggest 
that somatostatin has no effect on the sustained rise in [Ca”‘]i 
stimulated by both carbachol and gastrin. 
To conclude, our studies demonstrate that somatostatin 
is capable of inhibiting parietal cell activity stimulated by 
secretagogues that activate both adenylate cyclase and mem- 
brane inositol phospholipid turnover in a direct manner via 
a specific cell surface receptor. Part of its inhibitory action is 
mediated via a pertussis toxin-sensitive guanine nucleotide 
binding protein, but a component of its inhibitory action is 
insensitive to pertussis toxin and appears to occur at a distal 
site in various signal transduction cascades where stimulatory 
events converge to induce cell activation. This notion is sup 
ported by the observations that somatostatin may induce 
protein dephospho~lation*’ or inhibit exocytosis?” Somato- 
statin’s inhibitory action may occur even at the level of the 
nucleus. We have demonstrated recently that somatostatin 
is capable of inhibiting carbachol-mediated stimulation of 
carbonic anhydrase II and actin gene expression, elements 
that are important in the regulation of parietal cell activity. 
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